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Background & objectives: Incomplete adherence is a major contributor to failure of antiretroviral
therapy. Although the available methods to monitor adherence to therapy have proved to be
predictive of outcomes, the results are variable. We assessed the feasibility of detecting nevirapine
(NVP) in spot urine samples to monitor patient adherence to antiretroviral treatment and to study
the urinary excretion of NVP in healthy volunteers after oral administration of a single dose of
NVP (200 mg).
Methods: Spot urine samples were collected from 50 HIV-infected patients (36 on treatment regimen
containing NVP and 14 on drugs other than NVP) and tested for NVP by HPLC in a blinded
manner. Sixteen healthy volunteers (9 males and 7 females) were administered a single oral dose of
200 mg NVP and spot urine samples were collected on day ‘0’ before drug administration, and
thereafter every 24 h up to 9 days and tested for NVP.
Results: All the urine samples collected from patients undergoing treatment with NVP-containing
regimens at different time points after drug administration tested positive for NVP. Thirteen out
of 14 samples from patients not on NVP yielded a negative result. The drug was detected in the
urine of healthy volunteers up to 9 days. The urinary excretion of NVP was prolonged in females
than in males.
Interpretation & conclusion: In view of its long half-life, NVP gets excreted in urine for a long
period of time. Hence, testing spot urine samples for NVP may not be a useful measure to monitor
patient adherence to treatment.
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The use of a potent combination of antiretroviral
drugs has led to dramatic reductions in the morbidity
and mortality associated with HIV-1 infection1.
However, about 20 per cent of therapy-naive
patients fail  to achieve adequate virological
response during their first year of triple therapy,
with approximately 20 per cent more patients
experiencing virological failure during the second
year2. Variability in response to antiretroviral agents
has been attributed, in part ,  to virological,
immunological, pharmacokinetic and adherence
differences between patients3. Non adherence to
therapy has been shown to be a major contributor
to failure of therapy4,5.
Currently available approaches to measure
adherence have notable limitations6 and individual
patient assessments by medical providers do not
accurately predict adherence7. Urine could serve as
an useful biological fluid for detecting drugs/
metabolites,  particularly to monitor patient
adherence to treatment. Though nevirapine (NVP)
and its metabolites have been characterized in
urine8, no attempt has been made to use these as a
test for adherence. We, therefore, undertook an
investigation to test the usefulness of detecting NVP
in spot urine samples to monitor patient adherence
to antiretroviral treatment. The reason for choosing
NVP was that it is present in the fixed dose triple
drug combination of antiretroviral drugs that is
commonly used by HIV-infected patients. We also
studied the urinary excretion of NVP in healthy
volunteers after oral administration of a single dose
of NVP.
Material & Methods
Patients : Fifty consecutive HIV-seropositive
patients, aged 20 to 54 yr, attending the outpatient
clinic at the Tuberculosis Research Centre, Chennai,
India, during August - September 2004 took part in
this study. Of them, 36 patients were undergoing
antiretroviral treatment consisting of NVP (200 mg)
and lamivudine (150 mg) with either stavudine (30/
40 mg) or zidovudine (300 mg) twice daily. The
remaining 14 patients served as controls. On the day
of their visit to the clinic for routine examination,
the patients were asked to provide a spot urine
sample. None of the patients was previously informed
about the study. The urine samples were coded and
sent to the laboratory for urine NVP test.
Healthy volunteers: The healthy volunteers were 16
(9 males and 7 females) willing staff members
working at the Tuberculosis Research Centre. Their
age ranged from 28 to 54 yr. A sample of urine was
collected (day ‘0’) from all the healthy volunteers
followed by administration of NVP (200 mg). Urine
samples were collected every 24 h up to day 9. All
the urine samples were stored at -20oC until assays
were undertaken. Informed written consent was
obtained from all the healthy volunteers before they
took part in the study.
Determination of urine NVP: Nevirapine was tested in
all the urine samples by a high performance liquid
chromatography (HPLC) method described previously9.
In brief, NVP was extracted into ethyl acetate. The
organic layer was evaporated to dryness and the dried
residue was reconstituted in the mobile phase and
injected into the HPLC column. The HPLC system
(Shimadzu Corporation, Kyoto, Japan) consisted of two
pumps (LC-10ATvp), diode array detector (SPD-M
10AVP) and system controller (SCL-10AVP). A
rheodyne manual injector (Rheodyne, Cotati, CA, USA)
attached with a 20 µl sample loop was used for loading
the samples. Class VP-LC workstation was used for
data collection and acquisition. The analytical column
was a C18 250 x 4.6 mm internal diameter, 5µ particle
size (Lichrospher 100 RP-19e, Merck, Germany)
protected by a compatible guard column.
The mobile phase consisted of 50 mM phosphate
buffer, pH 4.6 and acetonitrile (83:17 v/v) containing
0.1 per cent triethylamine (v/v). The UV detector was
set at 245 nm. The chromatogram was run for 20 min
at a flow rate of 1.0 ml/min at a column temperature
of 40oC. Pure NVP solutions prepared in pooled urine
were processed along with test samples in a similar
manner and run every day.  Under these
chromatographic conditions, a retention time of 15 min
was obtained for NVP. The presence of a visible peak
around 15 min was considered to be positive for NVP.
Results & Discussion
Thirty six HIV-positive patients on treatment
regimens with NVP were receiving antiretroviral
treatment for a period ranging from 2 to 33 months.
The time of urine collection after drug administration
ranged from 20 min to 14 h. All the urine samples
collected from these patients tested positive for NVP,
as evidenced by a distinct peak at around 15 min.
Standard NVP aided in identifying the peak, in the
event of slight day-to-day variations in the retention
time of NVP. The method for determination of urine
NVP employed in this study was highly sensitive and
was able to detect NVP concentrations as low as
0.01µg/ml. Although specificity of the method had
been established by us, where interference due to
co-administered drugs, namely, lamivudine,
stavudine and zidovudine, was ruled out, this aspect
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was further strengthened by the fact that 13 out of 14
urine samples of patients not on NVP treatment, were
found to be negative for NVP. The single false positive
result could be due to an unknown endogenous
compound being eluted with the same retention time
as that of NVP. Thus, the accuracy of this method was
found to be 98 per cent. The method of Erickson et al9
to measure NVP and its metabolites formed under in
vitro conditions, was successfully used to determine
NVP qualitatively in urine in this study.
It was observed that all the urine samples collected
from 20 min to 14 h, after an oral dose, tested positive
for NVP. This could be due to the fact that NVP has a
long half - life of 25 to 30 h at steady state. It is
therefore expected that NVP would be excreted in
urine for a prolonged period. This was confirmed in
our study, where we found that 10 out of 16 healthy
volunteers excreted NVP up to nine days after a single
oral dose of 200 mg NVP.  We further observed that
majority of the male volunteers stopped excreting the
drug by day 6, while all, but one, female volunteers
continued to excrete NVP even up to
9 days (Fig.). This probably implies that females retain
the drug in their system for a longer time period than
males. This is in agreement with an earlier report on
sex-related differences in selected pharmacokinetic
parameters, mentioning that females have 20 per cent
higher exposure of NVP than males10.
Several reports have emphasized that non adherence
is the main cause for the failure of antiretroviral
therapy11,12. Methods used to gauge adherence include
patients’ self-report and physician assessments,
electronic monitoring, pill count, and prescription - refill
compliance. These methods have proved to be
predictive of outcomes, although the results are
variable13. Identifying additional accurate predictors of
adherence that can routinely be applied in clinical
practice may be of clinical value. Some investigators
have assessed the antiretroviral drug level in blood as a
measure of adherence14,15. Alternatively, urine levels of
antiretroviral drugs could serve as predictors to monitor
patient adherence to treatment if found to be feasible.
This method would be non-invasive and simple to
perform. This approach is being used in tuberculosis
therapy, where detection of acetyl isoniazid in urine
indicates intake of isoniazid within the past 24 h16.
In this study, we attempted to assess if a simple
spot urine test for NVP could help in monitoring
patient adherence to antiretroviral treatment.
Fig. Urinary excretion of nevirapine in healthy volunteers. Excretion of nevirapine studied in spot urine samples collected from
healthy volunteers (9 males and 7 females) up to 9 days following oral administration of a single dose of 200 mg nevirapine.
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However, in view of the long half-life of the drug
and prolonged excretion in urine, this test may not
be useful to check adherence to treatment. One reason
why all the 36 patients’ urine samples turned out to
be positive for NVP could be due to the fact that
patients tend to take their drugs without fail on their
scheduled visit to the Centre. A few missed doses, a
day or two prior to the test day would not be detected
by this method.  It may therefore, be more appropriate
to develop a urine test to check for the presence of
lamivudine, since this drug has a shorter half-life and
is present in the fixed dose combination pill taken
by HIV-infected patients. A simple urine test would
go a long way in monitoring antiretroviral adherence
in resource-constrained settings.
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